S

Sanofi

Global pharma company; vaccines and R&D

Technologist

Full-TimePosted on 10/21/2026Deadline 10/28/26
$49.34/hr
Mid
Bachelor's, Master's
Toronto, ON, Canada
In PersonOnsite in Toronto; Monday–Friday, 10:00 AM–6:00 PM.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A four-year Bachelor's degree in Microbiology and at least two years of previous relevant work experience, or a four-year Bachelor's degree plus a two-year Master's degree in Microbiology and at least eighteen months of previous relevant work experience.
  • Knowledge of microbiological methodology, aseptic technique, and microscopy.
  • Well-developed computer skills.
  • Strong verbal and written communication skills.
  • Judgement, self-initiative and focus, accuracy, and attention to detail.
  • Ability to work in a team environment and cooperate across functions.
Responsibilities
  • Receive test samples and transfer them to the appropriate testing area.
  • Perform testing, read results, and report results.
  • Submit microbial colonies recovered from testing for identification when appropriate.
  • Prepare cultures and perform relevant microbial identity tests when appropriate.
  • Communicate and resolve issues with the TGL/Manager or appropriate department.
  • Assist with troubleshooting invalid or unexpected results and coordinate the testing schedule as required.
  • Complete LIMS and SAP functions for testing activities accurately and on time; communicate with the Manager and QC planner to resolve outstanding items in SAP/LIMS and related issues.
  • Compile data summaries or trending reports with graphs and tables as needed.
  • Follow GMP/GLP and safety practices.
  • Maintain compliance in daily activities by following applicable SOPs, protocols, and procedures, and observe good documentation practices.
  • Review and verify test results performed by other analysts.
  • Identify and notify the Manager of laboratory non-conformances.
  • File deviation reports as necessary and provide supporting documentation to expedite their closure.
  • Participate in laboratory investigations and assist the lead investigator in preparing investigation reports.
  • Participate in root cause analysis to identify appropriate corrective actions for CAPAs and events.
  • Act as a Change Control Initiator or Leader as needed.
  • Create and reconcile controlled testing worksheets in the Electronic Document Management system.
  • Maintain the work area, clean the facility, maintain equipment, and dispose of hazardous waste.
  • Monitor and maintain inventory of test-related materials and supplies; liaise with purchasing, receiving, and vendors.
  • Complete and maintain cleaning, equipment, and related logs and records according to established procedures.
  • Report damage or abnormalities to the TGL/Manager or Security, and file and follow up on notifications for equipment, cleaning, and maintenance services.
  • Complete on-the-job training according to current lesson plans and document it as required; attend relevant training sessions.
  • Continuously review relevant SOPs and literature.
  • Participate in scheduled GMP updates and safety training, and attend departmental and safety meetings.
  • Contribute to establishing departmental training programs and assist in training new or existing personnel as required.
  • Write and train on validation protocols and reports.
  • Prepare data and documents using the company's approved format.
  • Assist the Manager/TGL in planning or coordinating project activities.
  • Attend team meetings and perform the respective tests as required.
  • Compile data summaries with graphs and tables and prepare reports as needed.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...